Protara Therapeutics, Inc. — Director's Dealing 2015

Oct 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2015-10-01

Reporting Person: NOYES TIMOTHY P (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-01	Common Stock	M	5000	$1.91	Acquired	5000	Direct
2015-10-01	Common Stock	S	5000	$13.33	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-10-01	Stock Option (Right to Buy)	$1.91	M	5000	Disposed	2016-04-19	Common Stock, $0.001 par value (5000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015.

F2: All shares were sold at a price of $13.33 per share.

F3: The option was granted on April 19, 2006. All shares underlying the option have vested.